1. Articles in category: PubMed

    1-24 of 1200 1 2 3 4 ... 48 49 50 »
    1. Desogestrel DOWN-REGULATES PHOX2B And Its Target Genes In Progesterone Responsive Neuroblastoma Cells.

      DESOGESTREL DOWN-REGULATES PHOX2B AND ITS TARGET GENES IN PROGESTERONE RESPONSIVE NEUROBLASTOMA CELLS.

      Exp Cell Res. 2018 Jul 20;:

      Authors: Cardani S, Di Lascio S, Belperio D, Di Biase E, Ceccherini I, Benfante R, Fornasari D

      Abstract The paired-like homeobox 2B gene (PHOX2B) encodes a key transcription factor that plays a role in the development of the autonomic nervous system and the neural structures involved in controlling breathing.

      Read Full Article
      Mentions: PHOX2B
    2. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.

      GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.

      Apoptosis. 2018 Jul 19;:

      Authors: Durbas M, Pabisz P, Wawak K, Wiśniewska A, Boratyn E, Nowak I, Horwacik I, Woźnicka O, Rokita H

      Read Full Article
      Mentions: Antibody
    3. Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

      Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

      J Pediatr Surg. 2018 Jul 06;:

      Authors: Fahy AS, Roberts A, Nasr A, Irwin MS, Gerstle JT

      Abstract PURPOSE: The impact of the extent of surgical resection including nephrectomy for high-risk neuroblastoma patients is controversial.

      Read Full Article
      Mentions: Surgery
    4. Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Proc Natl Acad Sci U S A. 2018 Jul 18;:

      Authors: Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Török Z, Laine A, Westermarck J, Bronner ME

      Read Full Article
      Mentions: MYCN
    5. Parental perception of child vulnerability in childhood cancer survivors.

      Parental perception of child vulnerability in childhood cancer survivors.

      Pediatr Blood Cancer. 2018 Jul 19;:e27364

      Authors: Staba Hogan MJ, Ross WL, Balsamo L, Mitchell HR, Kadan-Lottick NS

      Abstract BACKGROUND: Parents' perception of their children's vulnerability to illness following cancer treatment is largely unknown, but is important to understand given known challenges of transitioning survivors to postcancer care.

      Read Full Article
      Mentions: Treatment
    6. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    7. An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      Oncotarget. 2018 Jun 26;9(49):29082-29096

      Authors: Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M, Mairs R

      Abstract Targeted radiotherapy of metastatic neuroblastoma using the somatostatin receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with lutetium-177 (177Lu-DOTATATE) is a promising strategy.

      Read Full Article
    8. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Biol Direct. 2018 Jul 16;13(1):14

      Authors: Suo C, Deng W, Vu TN, Li M, Shi L, Pawitan Y

      Abstract BACKGROUND: Neuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression.

      Read Full Article
      Mentions: MYCN
    9. Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Oncol Lett. 2018 Aug;16(2):2439-2443

      Authors: Zhang X, Li C, Xu C, Hao X, Yu X, Li Q

      Abstract Correlation between computed tomography (CT) signs, lymphatic metastasis and pathological features of neuroblastoma (NB) in children was investigated.

      Read Full Article
      Mentions: Metastasis
    10. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Pediatr Blood Cancer. 2018 Jul 14;:e27354

      Authors: Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, Saveliev LI, Tytgat GAM, Fechina LG

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    11. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.

      Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.

      Molecules. 2018 Jul 02;23(7):

      Authors: Jiang CH, Huang CX, Chen YJ, Chuang YC, Huang BY, Yang CN

      Abstract Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in various cancers. In its basal state, the structure of ALK is in an autoinhibitory form stabilized by its A-loop, which runs from the N-lobe to the C-lobe of the kinase.

      Read Full Article
      Mentions: ALK
    12. Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Asia Ocean J Nucl Med Biol. 2018;6(2):161-166

      Authors: Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S

      Read Full Article
      Mentions: MIBG Chemotherapy
    13. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Br J Cancer. 2018 Jul 11;:

      Authors: Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T

      Read Full Article
      Mentions: GPOH Chemotherapy
    14. Somatic mutations in specific and connected sub-pathways are associated to short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.

      Somatic mutations in specific and connected sub-pathways are associated to short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.

      Int J Cancer. 2018 Jul 11;:

      Authors: Esposito MR, Binatti A, Pantile M, Coppe A, Mazzocco K, Longo L, Capasso M, Lasorsa VA, Luksch R, Bortoluzzi S, Tonini GP

      Read Full Article
    15. Clinical And Epidemiological Characteristics And Survival Outcomes Of Children With Neuroblastoma: 21 Years Of Experience At The Instituto De Oncologia PediÁtrica, In SÃo Paulo, Brazil.

      CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF CHILDREN WITH NEUROBLASTOMA: 21 YEARS OF EXPERIENCE AT THE INSTITUTO DE ONCOLOGIA PEDIÁTRICA, IN SÃO PAULO, BRAZIL.

      Rev Paul Pediatr. 2018 Jul 10;:

      Authors: Lucena JN, Alves MTS, Abib SCV, Souza GO, Neves RPC, Caran EMM

      Read Full Article
    16. Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.

      Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.

      Cancer Cell Int. 2018;18:82

      Authors: Uhl KL, Schultz CR, Geerts D, Bachmann AS

      Abstract Background: Neuroblastoma (NB) is an early childhood malignancy that arises from the developing sympathetic nervous system. Harmine is a tricyclic β-carboline alkaloid isolated from the harmal plant that exhibits both cytostatic and cytotoxic effects.

      Read Full Article
      Mentions: MYCN
    17. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

      Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

      Cochrane Database Syst Rev. 2018 Jul 05;7:CD010885

      Authors: van As JW, van den Berg H, van Dalen EC

      Abstract BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity.

      Read Full Article
      Mentions: Hearing Loss
    18. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      Front Immunol. 2018;9:1355

      Authors: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL

      Read Full Article
      Mentions: Antibody COG
    19. S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.

      S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.

      Oncol Lett. 2018 Jul;16(1):1023-1030

      Authors: Wu W, Jingbo S, Xu W, Liu J, Huang Y, Sheng Q, Lv Z

      Abstract Eg5 is a member of the kinesin-5 family. It is involved in the formation of the bipolar spindle and serves a crucial role in mitosis; meaning that mitotic activation may serve as a chemotherapeutic strategy.

      Read Full Article
    20. P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

      P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

      Apoptosis. 2018 Jun 29;:

      Authors: Hua Z, Zhan Y, Zhang S, Dong Y, Jiang M, Tan F, Liu Z, Thiele CJ, Li Z

      Read Full Article
    1-24 of 1200 1 2 3 4 ... 48 49 50 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles